Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
Skye Bioscience Announces $7.0 Million Registered Direct Offering
09:30am, Monday, 27'th Sep 2021
SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-deriv
Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference
08:30am, Wednesday, 11'th Aug 2021
SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
08:30am, Tuesday, 10'th Aug 2021
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies
Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program
08:30am, Thursday, 22'nd Apr 2021
San Diego, Calif, April 22, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-de
Skye Bioscience to Present at Upcoming Investment Conferences in April
08:45am, Thursday, 15'th Apr 2021
San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-de
Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids
01:09pm, Thursday, 08'th Apr 2021
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on t
Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug
09:02am, Tuesday, 23'rd Feb 2021
The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is in
Skye Bioscience to Participate in Investment Conferences in February
09:09am, Wednesday, 03'rd Feb 2021
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic can
Skye Bioscience Is Utilizing A Novel THC-Derivative To Treat Glaucoma
08:07am, Wednesday, 20'th Jan 2021
Skye Bioscience, formally Emerald Bioscience, was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in
